Atlas Trials

Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™

Clinical trial NCT03936426 · COMPLETED

Trial details

NCT number
NCT03936426
Sponsor
Clarity Pharmaceuticals Ltd
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Meningioma
Start date
2018-07-09
Primary completion
2019-09-19
Enrollment
5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.